SMSandra Meyer-Moock

Sandra Meyer-Moock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandra Meyer-Moock has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cultural adaptation of the Work Disability Functional Assessment Battery (WD-FAB) into German (Germany): hybrid application of two adaptation approaches

    by You-Shan Feng, Sandra Meyer-Moock, Maresa Buchholz, Elizabeth Marfeo, Julia Porcino, Susanne Weinbrenner, Jörg Gehrke, Lewis E. Kazis, Thomas Kohlmann

    Background: The Work Disability Functional Assessment Battery (WD-FAB) was developed based on the International Classification of Functioning, Disability and Health (ICF) framework and administered using a computer adaptive test (CAT) to assess individuals’ functional status. The framework and assessment of functional status is especially pertinent in Germany as one factor in determining work disability. This paper reports on the translation and cultural adaptation of the WD-FAB from English (USA) to German (Germany). Methodology: A combination of forward-backward and dual-panel approaches was used to translate the WD-FAB into German. During the reconciliation process after forward and backward translations, a selection of items was discussed with the forward/backward certified translators, discussed with developers of the WD-FAB and selected for dual-panel discussion. A field test with rehabilitation patients was conducted to finalize the adaptation. Results: 401 unique items from the original WD-FAB and version 3.0 (the majority of the items were the same across versions) were translated into German. After forward translation, the majority of the items were easily reconciled. Some items (identified by YF and TK) could not be easily reconciled and required additional examination. Based on the reasons for difficulties in forward translation, items were selected for the translation panel discussions ( n = 69), discussed with developers ( n = 49) and/or further discussed with the two forward translators ( n = 18). After the first reconciliation and backward translation, 31 items were discussed with all translators again and 4 were again discussed with developers. 77 rehabilitation patients participated in the field test, 29 of whom provided feedback suggesting further revisions. Through the entire adaptation process, the items that were problematic involved those dealing with “anger” and “stress”. Furthermore, environmental differences between Germany and the USA limited the adaptation of some physical functioning items. Conclusions: Despite some differences in the cultural and structural context, we successfully adapted the WD-FAB item banks to German. Future validation of the measure is necessary to understand whether the items have similar psychometric measurement properties to those of the original WD-FAB.

  • Open Access

    Konzepte der elterlichen Entscheidungsfindung zur Inanspruchnahme von Impfungen – eine qualitative Interviewstudie

    by Maresa Buchholz, Sandra Meyer-Moock, Bianca Biedenweg, Thomas Kohlmann

    Zusammenfassung: Hintergrund: Die ärztliche Impfberatung ist ein wichtiger Anker im Kontext impfpräventabler Erkrankungen. Unklar ist jedoch, welche Konstrukte der elterlichen Entscheidungsfindung bei impfskeptischen bis -ablehnenden Eltern bestehen. Ziel der Arbeit: Ziel der Arbeit ist die Untersuchung, welche Konstrukte der elterlichen Entscheidungsfindung dem (Nicht‑)Impfen zugrunde liegen und welche Rolle die ärztliche Impfberatung dabei spielt. Material und Methoden: Mittels qualitativer Fokusgruppengespräche wurden 11 Mütter mit mindestens einem Kind im Alter von 18–36 Monaten, das einen von der Ständigen Impfkommission (STIKO) abweichenden Impfplan aufwies, befragt. Die Interviews wurden auditiv aufgezeichnet, transkribiert und in Anlehnung an Mayring inhaltsanalytisch ausgewertet. Als theoretisches Konzept wurde die Partizipationspyramide nach Straßburger & Rieger (2019) herangezogen und mit den Ergebnissen abgeglichen. Ergebnisse: Alle Teilnehmerinnen standen dem Thema Impfen skeptisch bis ablehnend gegenüber. Ihre Entscheidung gegen den Impfplan der STIKO basierte vor allem auf der eigeninitiierten Selbstinformation und der damit verbundenen individuellen Risikoeinschätzung für die Kinder. Die auf Selbstinformation aufgebaute elterliche Expertise konkurrierte dabei mit der ärztlichen Wissensbasis. Darüber hinaus konnten 3 Typen der elterlichen Entscheidungsfindung identifiziert werden: (1) der medizinisch-paternalistische Typus (impfbefürwortend), (2) der partizipative Typus und (3) der Typus der elterlichen Selbstbestimmung (impfablehnend). Schlussfolgerung: Die Ergebnisse liefern Hinweise für die Verankerung einer partizipativ orientierten ärztlichen Impfberatung, um (1) die Kommunikation zwischen Eltern und Behandelnden zu verbessern und daraus resultierend (2) die Impfbereitschaft zu erhöhen. Darüber hinaus sollte die Bedeutung der ärztlichen Impfberatung im sozialrechtlichen Kontext stärker betont und nicht nur unter medizinischen Aspekten betrachtet werden.

  • Open Access

    PAIN2.0: study protocol for a multicentre randomised controlled trial to evaluate the efficacy of a 10-week outpatient interdisciplinary multimodal pain therapy to manage recurrent pain for patients with risk factors of developing chronic pain in Germany—update

    by Sandra Meyer-Moock, Daniel Szczotkowski, Leonie Schouten, Frank Petzke, Lena Milch, Beatrice Metz-Oster, Louise Zinndorf, Christian Geber, Greta Hoffmann, Anke Preißler, et al.

    Background: Up to 27% of the German population suffers from recurrent or persistent pain (lasting more than 3 months). Therefore, prevention of chronic pain is one major object of pain management interventions. The aim of this nationwide, multicentre, randomised controlled trial is to evaluate the efficacy of a 10-week ambulatory (outpatient) interdisciplinary multimodal pain therapy (A-IMPT) for patients with recurrent pain and at risk of developing chronic pain. This project was initiated by the German Pain Society (Deutsche Schmerzgesellschaft e.V.) and the public health insurance provider BARMER. It is currently funded by the German Innovation Fund (01NVF20023). The study PAIN2.0 focuses on reducing pain intensity and pain-related disability and investigates whether this intervention can improve physical activity, psychological well-being, and health literacy. Methods: PAIN2.0 is designed as a multicentre 1:1 randomised controlled trial with two parallel groups (randomisation at the patient level, planned N = 1029, duration of study participation 12 months, implemented by 22 health care facilities nationwide). After 6 months, patients within the control group also receive the intervention. The primary outcomes are pain intensity and pain-related impairment, measured as Characteristic Pain Intensity (PI) and Disability Score (DS) (Von Korff) (baseline to 6 months follow-up). Secondary outcomes are the number of sick leave days, sickness allowance, treatment costs, psychological distress, health-related quality of life, catastrophising, and patient-related satisfaction with the intervention. The effects of the intervention will be analysed by a parallel-group comparison between the intervention and control groups. In addition, the long-term effects within the intervention group will be observed and a pre-post comparison of the control group before and after the intervention will be performed. Discussion: Recurrent or persistent pain is common in the German population and causes high costs for patients and society. The A-IMPT aims to improve pain and pain-related impairments in pain patients at risk of chronification, thereby reducing the risk of developing chronic pain with its high socioeconomic burden. This new therapy could easily be integrated into existing therapy programs if positively evaluated. Trial registration The trial PAIN2.0 has been registered in the German Clinical Trials Register (DRKS) since 21/11/2022 with the ID DRKS00030773 [ https://drks.de/search/de/trial/DRKS00030773 ]. This publication provides an update to the original study protocol, which was first published on 23 February 2024 [https://doi.org/10.1186/s13063-024-07975-4, BMC Trials]. Due to recruitment problems during the course of the project, the originally planned number of cases could not be achieved. In order to be able to provide sufficient information about the primary effects of the study, the number of primary endpoints was reduced from 3 to 2. The primary analysis period is now 6 months without including an additional measurement point after 3 months.


  • Open Access

    Evaluating an early Interdisciplinary Multimodal Assessment for Patients at Risk of Developing Chronic Pain: Results of a Multicentre RCT in Germany

    by Daniel Szczotkowski, Sandra Meyer-Moock, Thomas Kohlmann, Karin Deppe, Anne Gärtner, Greta Hoffmann, Thomas Isenberg, Gabriele Lindena, Ursula Marschall, Carolin Martin, et al.

    Introduction Patients at risk of developing chronic pain are often significantly impaired in their daily, social and work activities. An early interdisciplinary multimodal assessment (IMA) includes a systematically integrated view of medical, psychosocial and functional factors to direct patients to need-based treatment services. This multicentre, randomised, controlled trial examined the effects of an IMA on preventing chronic pain and improving care for adult patients. Methods The intervention group (IG) received an IMA in accordance with standardised guidelines. The control group (CG) was offered a unimodal medical pain assessment (MPA). Data from the Characteristic Pain Intensity (PI) and Disability Score (DS), as primary outcomes, were collected at assessment and 3 and 6 months later together with secondary outcomes (e.g. depression, anxiety, stress, catastrophizing, health-related quality of life). Results A total of 620 (68.4%) valid questionnaires were available at the 6-month follow-up. The mean reduction (numerical rating scale, 0–10) in terms of improvement within both groups (IG/CG) was 1.6/1.7 points for PI and 1.9/1.8 points for DS. Most secondary outcomes improved as well. However, the differences between the two groups did not reach statistical significance, although there was a tendency for the IG to have a greater effect on some psychological outcomes. Regarding the recommended treatment approaches, the focus in the IG was more on physical activity and psychological and psychosomatic interventions, whereas in the CG there was also a preference for adjusting the medication. Conclusions Both early MPA and IMA seem to have a positive effect on outcomes such as pain intensity, functional limitations and psychological factors for patients at risk of developing chronic pain. We critically reflect on the results of the primary research question by discussing the limitations in detail and conclude that further research should ensure that the control conditions reflect standard care and that the follow-up period is long enough. Trial registration German Clinical Trials Register (DRKS-ID: DRKS00015443).


  • Open Access

    PAIN2.0: study protocol for a multicentre randomised controlled trial to evaluate the efficacy of a 10-week outpatient interdisciplinary multimodal pain therapy to manage recurrent pain for patients with risk factors of developing chronic pain in Germany

    by Sandra Meyer-Moock, Daniel Szczotkowski, Leonie Schouten, Frank Petzke, Lena Milch, Beatrice Metz-Oster, Louise Zinndorf, Christian Geber, Greta Hoffmann, Anke Preißler, et al.

    Background: Up to 27% of the German population suffers from recurrent or persistent pain (lasting more than three months). Therefore, prevention of chronic pain is one major object of pain management interventions. The aim of this nationwide, multicentre, randomised controlled trial is to evaluate the efficacy of a 10-week ambulatory (outpatient) interdisciplinary multimodal pain therapy (A-IMPT) for patients with recurrent pain and at risk of developing chronic pain. This project was initiated by the German Pain Society (Deutsche Schmerzgesellschaft e.V.) and the public health insurance provider BARMER. It is currently funded by the German Innovation Fund (01NVF20023). The study PAIN2.0 focuses on reducing pain intensity and pain-related disability and investigates whether this intervention can improve physical activity, psychological well-being, and health literacy. Methods: PAIN2.0 is designed as a multicentre 1:1 randomised controlled trial with two parallel groups (randomisation at the patient level, planned N = 1094, duration of study participation 12 months, implemented by 22 health care facilities nationwide). After 6 months, patients within the control group also receive the intervention. The primary outcomes are pain intensity and pain-related impairment, measured as Characteristic Pain Intensity (PI) and Disability Score (DS) (Von Korff), as well as patient-related satisfaction with the intervention. Secondary outcomes are the number of sick leave days, sickness allowance, treatment costs, psychological distress, health-related quality of life, and catastrophizing. The effects of the intervention will be analysed by a parallel-group comparison between the intervention and control groups. In addition, the long-term effects within the intervention group will be observed and a pre-post comparison of the control group before and after the intervention will be performed. Discussion: Recurrent or persistent pain is common in the German population and causes high costs for patients and society. The A-IMPT aims to improve pain and pain-related impairments in pain patients at risk of chronification, thereby reducing the risk of developing chronic pain with its high socioeconomic burden. This new therapy could easily be integrated into existing therapy programs if positively evaluated. Trial registration: The trial PAIN2.0 has been registered in the German Clinical Trials Register (DRKS) since 21/11/2022 with the ID DRKS00030773 .


  • Open Access

    PAIN2.0: Study protocol for a multicentre randomised controlled trial to evaluate the efficacy of a 10-week outpatient interdisciplinary multimodal pain therapy to manage recurrent pain for patients with risk factors of developing chronic pain in Germany

    by Sandra Meyer-Moock, Daniel Szczotkowski, Leonie Schouten, Frank Petzke, Lena Milch, Beatrice Metz-Oster, Louise Zinndorf, Christian Geber, Greta Hoffmann, Anke Preißler, et al.

    Background: Up to 27% of the German population suffers from recurrent or persistent pain (lasting more than three months). Therefore, prevention of chronic pain is one major object of pain management interventions. The aim of this nationwide, multicentre, randomised controlled trial is to evaluate the efficacy of a 10-week ambulatory (outpatient) interdisciplinary multimodal pain therapy (A-IMPT) for patients with recurrent pain and at risk of developing chronic pain. This project was initiated by the German Pain Society (Deutsche Schmerzgesellschaft e.V.) and the public health insurance provider BARMER. It is currently funded by the German Innovation Fund (01NVF20023). The study PAIN2.0 focuses on reducing pain intensity and pain-related disability and investigates whether this intervention can improve physical activity, psychological well-being, and health literacy. Methods: PAIN2.0 is designed as a multicentre 1:1 randomised controlled trial with two parallel groups (randomisation at the patient level, planned N = 1094, duration of study participation 12 months, implemented by 22 health care facilities nationwide). After 6 months, patients within the control group also receive the intervention. The primary outcomes are pain intensity and pain-related impairment, measured as Characteristic Pain Intensity (PI) and Disability Score (DS) (Von Korff), as well as patient-related satisfaction with the intervention. Secondary outcomes are the number of sick leave days, sickness allowance, treatment costs, psychological distress, health-related quality of life, and catastrophizing. The effects of the intervention will be analysed by a parallel-group comparison between the intervention and control groups. In addition, the long-term effects within the intervention group will be observed and a pre-post comparison of the control group before and after the intervention will be performed. Discussion: Recurrent or persistent pain is common in the German population and causes high costs for patients and society. The A-IMPT aims to improve pain and pain-related impairments in pain patients at risk of chronification, thereby reducing the risk of developing chronic pain with its high socioeconomic burden. This new therapy could easily be integrated into existing therapy programs if positively evaluated. Trial registration: The trial PAIN2.0 has been registered in the German Clinical Trials Register (DRKS) since 21/11/2022 with the ID DRKS00030773 [https://drks.de/search/de/trial/DRKS00030773].

  • Open Access

    Strengthening the occupational and social participation of multiple sclerosis patients - design of a multicenter, parallel-group randomized controlled trial (MSnetWork-study)

    by Sandra Meyer-Moock, Susan Raths, Katharina Strunk, Bernward Siebert, Katrin Hinkfoth, Markus Weih, Steffen Fleßa, Thomas Kohlmann

    Background: Multiple Sclerosis is an autoimmune inflammatory disease of the central nervous system that often leads to premature incapacity for work. Therefore, the MSnetWork project implements a new form of care and pursues the goal of maintaining or even improving the state of health of MS patients and having a positive influence on their ability to work as well as their participation in social life. A network of neurologists, occupational health and rehabilitation physicians, psychologists, and social insurance suppliers provide patients with targeted services that have not previously been part of standard care. According to the patient’s needs treatment options will be identified and initiated. Methods: The MSnetWork study is designed as a multicenter randomized controlled trial, with two parallel groups (randomization at the patient level with 1:1 allocation ratio, planned N = 950, duration of study participation 24 months). After 12 months, the patients in the control group will also receive the interventions. The primary outcome is the number of sick leave days. Secondary outcomes are health-related quality of life, physical, affective and cognitive status, fatigue, costs of incapacity to work, treatment costs, out-of-pocket costs, self-efficacy, and patient satisfaction with therapy. Intervention effects are analyzed by a parallel-group comparison between the intervention and the control group. Furthermore, the long-term effects within the intervention group will be observed and a pre-post comparison of the control group, before and after receiving the intervention in MSnetWork, will be performed. Discussion: Due to the multiple approaches to patient-centered, multidisciplinary MS care, MSnetWork can be considered a complex intervention. The study design and linkage of comprehensive, patient-specific primary and secondary data in an outpatient setting enable the evaluation of this complex intervention, both on a qualitative and quantitative level. The basic assumption is a positive effect on the prevention or reduction of incapacity for work as well as on the patients’ quality of life. If the project proves to be a success, MSnetWork could be adapted for the treatment of other chronic diseases with an impact on the ability to work and quality of life. Trial registration: The trial MSnetWork has been retrospectively registered in the German Clinical Trials Register (DRKS) since 08.07.2022 with the ID DRKS00025451.